v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Financial Data for Reportable Segment

The following table presents certain financial data including significant segment expenses for the Company’s reportable segment for the three and six months ended June 30, 2026 and 2025 (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

ACR-368 direct research and development expenses

 

$

5,637

 

 

$

7,013

 

 

$

11,733

 

 

$

13,660

 

ACR-2316 direct research and development expenses

 

 

1,231

 

 

 

1,766

 

 

 

2,713

 

 

 

2,930

 

Other drug discovery programs direct research and development expenses

 

 

282

 

 

 

564

 

 

 

866

 

 

 

1,208

 

Personnel-related indirect research and development expenses

 

 

5,558

 

 

 

5,478

 

 

 

11,145

 

 

 

11,152

 

Facilities, supplies and other indirect research and development expenses

 

 

1,136

 

 

 

1,361

 

 

 

2,553

 

 

 

2,646

 

General and administrative expenses

 

 

4,824

 

 

 

6,467

 

 

 

9,560

 

 

 

12,715

 

Other segment items1

 

 

(704

)

 

 

(1,643

)

 

 

(1,564

)

 

 

(3,625

)

Net loss

 

$

(17,964

)

 

$

(21,006

)

 

$

(37,006

)

 

$

(40,686

)

 

1 Other segment items consist of interest income and other expense, net. Interest income consists of interest income earned on cash equivalents and investments and amortization of premiums and accretion of discounts to maturity for available-for-sale debt securities. Other expense, net primarily consists of realized and unrealized gains and losses on foreign currency transactions, state and franchise taxes, and investment management fees.